Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1152

1.

[Prescribing patterns of antiparkinson drugs in a group of Colombian patients, 2015].

Machado-Alba JE, Calvo-Torres LF, Gaviria-Mendoza A, Castrillón-Spitia JD.

Biomedica. 2018 Sep 1;38(3):417-426. doi: 10.7705/biomedica.v38i4.3781.

PMID:
30335247
2.

Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.

Pahwa R, Isaacson S, Jimenez-Shaheed J, Malaty IA, Deik A, Johnson R, Patni R.

Parkinsonism Relat Disord. 2018 Sep 5. pii: S1353-8020(18)30390-0. doi: 10.1016/j.parkreldis.2018.09.005. [Epub ahead of print]

3.

Efficacy of Amantadine in Improving Cognitive Dysfunction in Adults with Severe Traumatic Brain Injury in Indian Population: A Pilot Study.

Ghate PS, Bhanage A, Sarkar H, Katkar A.

Asian J Neurosurg. 2018 Jul-Sep;13(3):647-650. doi: 10.4103/ajns.AJNS_272_16.

4.

Parkinson's Disease: Biomarkers, Treatment, and Risk Factors.

Emamzadeh FN, Surguchov A.

Front Neurosci. 2018 Aug 30;12:612. doi: 10.3389/fnins.2018.00612. eCollection 2018. Review.

5.

What predicts falls in Parkinson disease?: Observations from the Parkinson's Foundation registry.

Parashos SA, Bloem BR, Browner NM, Giladi N, Gurevich T, Hausdorff JM, He Y, Lyons KE, Mari Z, Morgan JC, Post B, Schmidt PN, Wielinski CL.

Neurol Clin Pract. 2018 Jun;8(3):214-222. doi: 10.1212/CPJ.0000000000000461. Erratum in: Neurol Clin Pract. 2018 Aug;8(4):278.

PMID:
30105161
6.

Amantadine Extended-Release (GOCOVRI): A Review in Levodopa-Induced Dyskinesia in Parkinson's Disease.

Paik J, Keam SJ.

CNS Drugs. 2018 Aug;32(8):797-806. doi: 10.1007/s40263-018-0552-2.

PMID:
30088203
7.

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT.

J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7.

PMID:
30087157
8.

Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.

Speck AE, Schamne MG, S Aguiar A Jr, Cunha RA, Prediger RD.

Mol Neurobiol. 2018 Aug 2. doi: 10.1007/s12035-018-1278-3. [Epub ahead of print]

PMID:
30073506
9.

Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism.

Giagkou N, Stamelou M.

CNS Drugs. 2018 Sep;32(9):827-837. doi: 10.1007/s40263-018-0551-3. Review.

PMID:
30051337
10.

Treatment of psychotic symptoms in patients with Parkinson disease.

Chen JJ.

Ment Health Clin. 2018 Mar 23;7(6):262-270. doi: 10.9740/mhc.2017.11.262. eCollection 2017 Nov.

11.

Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease: An Exploratory Case-Control Study.

Ameghino L, Bruno V, Merello M.

Clin Neuropharmacol. 2018 Jul/Aug;41(4):123-128. doi: 10.1097/WNF.0000000000000285.

PMID:
29927803
12.

Use of anti-Parkinson medication during pregnancy: a case series.

Tüfekçioğlu Z, Hanağası H, Yalçın Çakmaklı G, Elibol B, Esmeli Tokuçoğlu F, Kaya ZE, Ertan S, Özekmekçi S, Emre M.

J Neurol. 2018 Aug;265(8):1922-1929. doi: 10.1007/s00415-018-8937-1. Epub 2018 Jun 20.

PMID:
29926223
13.

NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.

Vanle B, Olcott W, Jimenez J, Bashmi L, Danovitch I, IsHak WW.

Transl Psychiatry. 2018 Jun 15;8(1):117. doi: 10.1038/s41398-018-0162-2. Review.

14.

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson's Disease: An Open-Label, Pragmatic Trial.

Kim A, Kim YE, Yun JY, Kim HJ, Yang HJ, Lee WW, Shin CW, Park H, Jung YJ, Kim A, Kim Y, Jang M, Jeon B.

J Mov Disord. 2018 May;11(2):65-71. doi: 10.14802/jmd.18005. Epub 2018 May 30.

15.

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R.

Mov Disord Clin Pract. 2018 Mar-Apr;5(2):183-190. doi: 10.1002/mdc3.12595. Epub 2018 Feb 23.

16.

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.

Hauser RA, Pahwa R, Wargin WA, Souza-Prien CJ, McClure N, Johnson R, Nguyen JT, Patni R, Went GT.

Clin Pharmacokinet. 2018 May 18. doi: 10.1007/s40262-018-0663-4. [Epub ahead of print]

PMID:
29777529
17.

Update in therapeutic strategies for Parkinson's disease.

Kulisevsky J, Oliveira L, Fox SH.

Curr Opin Neurol. 2018 Aug;31(4):439-447. doi: 10.1097/WCO.0000000000000579.

PMID:
29746402
18.

[Therapy of Dementia: State of the Art].

Roeben B, Zieschang T, Maetzler W.

Dtsch Med Wochenschr. 2018 May;143(10):741-747. doi: 10.1055/s-0043-113619. Epub 2018 May 4. German.

PMID:
29727890
19.

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.

Sharma VD, Lyons KE, Pahwa R.

Ther Clin Risk Manag. 2018 Apr 12;14:665-673. doi: 10.2147/TCRM.S144481. eCollection 2018. Review.

20.

Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.

Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, Felt L, Johnson R, Patni R.

CNS Drugs. 2018 Apr;32(4):399-400. doi: 10.1007/s40263-018-0510-z.

PMID:
29637528

Supplemental Content

Loading ...
Support Center